Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Stroke

  Free Subscription


Articles published in Lancet Neurol

Retrieve available abstracts of 201 articles:
HTML format



Single Articles


    February 2025
  1. SHOAMANESH A, Field TS, Coutts SB, Sharma M, et al
    Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial.
    Lancet Neurol. 2025;24:140-151.
    PubMed     Abstract available


  2. LIU R, Zhao J, Rudd AG
    From stroke awareness to stroke action awareness.
    Lancet Neurol. 2025;24:96.
    PubMed    


  3. SPOSATO LA, Wachter R
    Anticoagulation for patients with device-detected atrial fibrillation and a history of stroke.
    Lancet Neurol. 2025;24:92-94.
    PubMed    


  4. MOENS TG, Da Cruz S, Neumann M, Shelkovnikova TA, et al
    Amyotrophic lateral sclerosis caused by FUS mutations: advances with broad implications.
    Lancet Neurol. 2025;24:166-178.
    PubMed     Abstract available


  5. COLEMAN KKL, Berry S, Cummings J, Hsiung GR, et al
    Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial.
    Lancet Neurol. 2025;24:128-139.
    PubMed     Abstract available


  6. HABIB AA, Zhao C, Aban I, Franca MC Jr, et al
    Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
    Lancet Neurol. 2025;24:117-127.
    PubMed     Abstract available


  7. ANTOZZI C, Vu T, Ramchandren S, Nowak RJ, et al
    Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.
    Lancet Neurol. 2025;24:105-116.
    PubMed     Abstract available


    January 2025
  8. YANG P, Zhang Y, Liu J
    Ischaemic stroke in 2024: progress on multiple fronts.
    Lancet Neurol. 2025;24:7-8.
    PubMed    


    December 2024
  9. GETTINGS JV, Mohammad Alizadeh Chafjiri F, Patel AA, Shorvon S, et al
    Diagnosis and management of status epilepticus: improving the status quo.
    Lancet Neurol. 2024 Dec 2:S1474-4422(24)00430.
    PubMed     Abstract available


  10. SHETH KN, Albers GW, Saver JL, Campbell BCV, et al
    Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial.
    Lancet Neurol. 2024;23:1205-1213.
    PubMed     Abstract available


  11. LIU Q, Mo S, Wu J, Tong X, et al
    Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, randomised trial.
    Lancet Neurol. 2024;23:1195-1204.
    PubMed     Abstract available


    November 2024
  12. TURC G, Nguyen TN
    Reconsidering prourokinase for acute ischaemic stroke.
    Lancet Neurol. 2024 Nov 28:S1474-4422(24)00474.
    PubMed    


  13. LI S, Gu HQ, Feng B, Li H, et al
    Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4.5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial.
    Lancet Neurol. 2024 Nov 28:S1474-4422(24)00436.
    PubMed     Abstract available


  14. KRUYT ND, Nederkoorn PJ, Sandset EC, Lyden P, et al
    A cautionary view on blood pressure lowering in patients with acute ischaemic stroke receiving reperfusion therapy.
    Lancet Neurol. 2024 Nov 25:S1474-4422(24)00438.
    PubMed    


  15. MUIR KW, Ford GA, Ford I, Wardlaw JM, et al
    Tenecteplase versus alteplase for acute stroke within 4.5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial.
    Lancet Neurol. 2024;23:1087-1096.
    PubMed     Abstract available


  16. BRALEY TJ, Ehde DM, Alschuler KN, Little R, et al
    Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm trial.
    Lancet Neurol. 2024;23:1108-1118.
    PubMed     Abstract available


  17. PALAIODIMOU L, Tsivgoulis G
    A new standard for thrombolysis in acute ischaemic stroke.
    Lancet Neurol. 2024;23:1064-1065.
    PubMed    


    October 2024
  18. LIM SY, Tan AH, Ahmad-Annuar A, Okubadejo NU, et al
    Uncovering the genetic basis of Parkinson's disease globally: from discoveries to the clinic.
    Lancet Neurol. 2024 Oct 21:S1474-4422(24)00378.
    PubMed     Abstract available


  19. VOLOVICI V, Cenzato M, Meling TR
    The European expertise network for open microvascular surgery.
    Lancet Neurol. 2024 Oct 11:S1474-4422(24)00409.
    PubMed    



  20. Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet Neurol. 2024;23:973-1003.
    PubMed     Abstract available


  21. WU S, Liu M
    Global burden of stroke: dynamic estimates to inform action.
    Lancet Neurol. 2024;23:952-953.
    PubMed    


  22. AMEZCUA L, Rotstein D, Shirani A, Ciccarelli O, et al
    Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, northern Europe, and Australasia.
    Lancet Neurol. 2024;23:1050-1062.
    PubMed     Abstract available


  23. CORREALE J, Solomon AJ, Cohen JA, Banwell BL, et al
    Differential diagnosis of suspected multiple sclerosis: global health considerations.
    Lancet Neurol. 2024;23:1035-1049.
    PubMed     Abstract available


    September 2024
  24. CANEVELLI M, Jackson-Tarlton C, Rockwood K
    Frailty for neurologists: perspectives on how frailty influences care planning.
    Lancet Neurol. 2024 Sep 11:S1474-4422(24)00291.
    PubMed     Abstract available


  25. OSPEL JM, Ganesh A, Goyal M
    Pragmatic outcomes for stroke research.
    Lancet Neurol. 2024;23:860-862.
    PubMed    


  26. YOGENDRAKUMAR V, Lin L, Medcalf RL, Parsons MW, et al
    Improving thrombolysis efficiency for acute ischaemic stroke.
    Lancet Neurol. 2024;23:853-855.
    PubMed    


    August 2024
  27. LABEIT B, Michou E, Trapl-Grundschober M, Suntrup-Krueger S, et al
    Dietary intervention for post-stroke dysphagia - Authors' reply.
    Lancet Neurol. 2024;23:764-765.
    PubMed    


  28. SHIMIZU A, Yamaguchi K, Kunieda K, Ohno T, et al
    Dietary intervention for post-stroke dysphagia.
    Lancet Neurol. 2024;23:763-764.
    PubMed    


  29. THE LANCET NEUROLOGY
    A real chance to reduce death and disability from stroke.
    Lancet Neurol. 2024;23:749.
    PubMed    


    July 2024
  30. MORIMOTO T, Sakakibara F
    Endovascular thrombectomy for large ischaemic stroke: outcomes beyond 90 days.
    Lancet Neurol. 2024 Jul 26:S1474-4422(24)00290.
    PubMed    


  31. THOMALLA G, Fiehler J, Subtil F, Bonekamp S, et al
    Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trial.
    Lancet Neurol. 2024 Jul 26:S1474-4422(24)00278.
    PubMed     Abstract available


  32. SCHULTZ SA, Liu L, Schultz AP, Fitzpatrick CD, et al
    gamma-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).
    Lancet Neurol. 2024 Jul 26:S1474-4422(24)00236.
    PubMed     Abstract available


  33. BOURCIER R, Marnat G, Dargazanli C, Zhu F, et al
    Safety and efficacy of stent retrievers plus contact aspiration in patients with acute ischaemic anterior circulation stroke and positive susceptibility vessel sign in France (VECTOR): a randomised, single-blind trial.
    Lancet Neurol. 2024;23:700-711.
    PubMed     Abstract available


  34. ABDALKADER M, Nguyen TN
    Susceptibility vessel sign and endovascular stroke therapy.
    Lancet Neurol. 2024;23:653-654.
    PubMed    


    June 2024
  35. GAO F, Tong X, Jia B, Wei M, et al
    Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial.
    Lancet Neurol. 2024 Jun 21:S1474-4422(24)00186.
    PubMed     Abstract available


  36. CAMPBELL BCV
    Durable benefit of thrombectomy 6-24 h after stroke onset.
    Lancet Neurol. 2024 Jun 20:S1474-4422(24)00261.
    PubMed    


  37. HUIJBERTS I, Pinckaers FME, Olthuis SGH, van Kuijk SMJ, et al
    Collateral-based selection for endovascular treatment of acute ischaemic stroke in the late window (MR CLEAN-LATE): 2-year follow-up of a phase 3, multicentre, open-label, randomised controlled trial in the Netherlands.
    Lancet Neurol. 2024 Jun 20:S1474-4422(24)00228.
    PubMed     Abstract available


  38. PARSONS MW, Yogendrakumar V, Churilov L, Garcia-Esperon C, et al
    Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4.5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial.
    Lancet Neurol. 2024 Jun 13:S1474-4422(24)00206.
    PubMed     Abstract available


  39. TOYODA K
    Tenecteplase versus alteplase in stroke thrombolysis: the last piece of the puzzle?
    Lancet Neurol. 2024 Jun 13:S1474-4422(24)00258.
    PubMed    


  40. ALI M, van Etten ES, Akoudad S, Schaafsma JD, et al
    Haemorrhagic stroke and brain vascular malformations in women: risk factors and clinical features.
    Lancet Neurol. 2024;23:625-635.
    PubMed     Abstract available


  41. THE LANCET NEUROLOGY
    Forging ahead in haemorrhagic stroke research.
    Lancet Neurol. 2024;23:545.
    PubMed    


  42. SISODIYA SM, Gulcebi MI, Fortunato F, Mills JD, et al
    Climate change and disorders of the nervous system.
    Lancet Neurol. 2024;23:636-648.
    PubMed     Abstract available


    May 2024
  43. OLAVARRIA VV
    Challenging the management of blood pressure before intravenous thrombolysis in acute ischaemic stroke.
    Lancet Neurol. 2024 May 15:S1474-4422(24)00208.
    PubMed    


  44. ZONNEVELD TP, Vermeer SE, van Zwet EW, Groot AED, et al
    Safety and efficacy of active blood-pressure reduction to the recommended thresholds for intravenous thrombolysis in patients with acute ischaemic stroke in the Netherlands (TRUTH): a prospective, observational, cluster-based, parallel-group study.
    Lancet Neurol. 2024 May 15:S1474-4422(24)00177.
    PubMed     Abstract available


  45. SARFO FS, Gebreyohanns M, Akinyemi R, Ebenezer AA, et al
    The African Stroke Organization Conference 2023.
    Lancet Neurol. 2024;23:459-460.
    PubMed    


  46. CORTESE I, Norato G, Harrington PR, Usher T, et al
    Biomarkers for progressive multifocal leukoencephalopathy: emerging data for use of JC virus DNA copy number in clinical trials.
    Lancet Neurol. 2024;23:534-544.
    PubMed     Abstract available


  47. PELLINEN J, Foster EC, Wilmshurst JM, Zuberi SM, et al
    Improving epilepsy diagnosis across the lifespan: approaches and innovations.
    Lancet Neurol. 2024;23:511-521.
    PubMed     Abstract available


    April 2024
  48. YASSI N, Zhao H, Churilov L, Wu TY, et al
    Tranexamic acid versus placebo in individuals with intracerebral haemorrhage treated within 2 h of symptom onset (STOP-MSU): an international, double-blind, randomised, phase 2 trial.
    Lancet Neurol. 2024 Apr 19:S1474-4422(24)00128.
    PubMed     Abstract available



  49. Medical management and surgery versus medical management alone for symptomatic cerebral cavernous malformation (CARE): a feasibility study and randomised, open, pragmatic, pilot phase trial.
    Lancet Neurol. 2024 Apr 17:S1474-4422(24)00096.
    PubMed     Abstract available


  50. GUSTAVSSON EK, Follett J, Trinh J, Barodia SK, et al
    RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses.
    Lancet Neurol. 2024 Apr 10:S1474-4422(24)00121.
    PubMed     Abstract available


  51. LABEIT B, Michou E, Trapl-Grundschober M, Suntrup-Krueger S, et al
    Dysphagia after stroke: research advances in treatment interventions.
    Lancet Neurol. 2024;23:418-428.
    PubMed     Abstract available


  52. SEIFFGE DJ, Cancelloni V, Raber L, Paciaroni M, et al
    Secondary stroke prevention in people with atrial fibrillation: treatments and trials.
    Lancet Neurol. 2024;23:404-417.
    PubMed     Abstract available


  53. SPOSATO LA, Andrade JG, Field TS
    Detection of atrial fibrillation in patients after stroke - Authors' reply.
    Lancet Neurol. 2024;23:336-337.
    PubMed    


  54. SIONTIS KC, Noseworthy PA, Friedman PA
    Detection of atrial fibrillation in patients after stroke.
    Lancet Neurol. 2024;23:335-336.
    PubMed    


  55. KANDEL A, Arjyal A, Karmacharya B, Gajurel B, et al
    Pragmatic solutions for the global burden of stroke.
    Lancet Neurol. 2024;23:334.
    PubMed    


  56. FEIGIN VL, Yaria J, Owolabi M
    Pragmatic solutions for the global burden of stroke - Authors' reply.
    Lancet Neurol. 2024;23:334-335.
    PubMed    


  57. SCHLOGL M, Quinn TJ
    Pragmatic solutions for the global burden of stroke.
    Lancet Neurol. 2024;23:333-334.
    PubMed    



  58. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet Neurol. 2024;23:344-381.
    PubMed     Abstract available


    February 2024
  59. MAZIGHI M, Kohrmann M, Lemmens R, Lyrer PA, et al
    Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial.
    Lancet Neurol. 2024;23:157-167.
    PubMed     Abstract available


  60. GANESH A
    Platelet glycoprotein VI inhibition: a promising therapeutic avenue in acute ischaemic stroke.
    Lancet Neurol. 2024;23:125-127.
    PubMed    


  61. SIMUNI T, Chahine LM, Poston K, Brumm M, et al
    A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research.
    Lancet Neurol. 2024;23:178-190.
    PubMed     Abstract available


  62. CHAPLEAU M, La Joie R, Yong K, Agosta F, et al
    Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.
    Lancet Neurol. 2024;23:168-177.
    PubMed     Abstract available


    January 2024
  63. SHARMA M, Molina CA, Toyoda K, Bereczki D, et al
    Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.
    Lancet Neurol. 2024;23:46-59.
    PubMed     Abstract available


  64. KHATRI P
    Anticoagulants to prevent recurrent non-cardioembolic stroke.
    Lancet Neurol. 2024;23:3-5.
    PubMed    


  65. ANDERSON CS
    Stroke advances in 2023: a new horizon for the management of intracerebral haemorrhage.
    Lancet Neurol. 2024;23:12-13.
    PubMed    


    December 2023
  66. BRIGO F
    The (hi)story of stroke.
    Lancet Neurol. 2023;22:1110.
    PubMed    


  67. UCHIYAMA S
    Anticoagulation in people with atrial fibrillation after intracranial haemorrhage.
    Lancet Neurol. 2023;22:1091-1092.
    PubMed    


  68. ABBOTT A, Schott L, Gao L, Budincevic H, et al
    Carotid artery overtreatment in the USA.
    Lancet Neurol. 2023;22:1102-1103.
    PubMed    


    November 2023
  69. KOPCZAK A, Stringer MS, van den Brink H, Kerkhofs D, et al
    Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial.
    Lancet Neurol. 2023;22:991-1004.
    PubMed     Abstract available


  70. RUBIANO AM, Lee K
    Traumatic brain injury research: homogenising heterogeneity.
    Lancet Neurol. 2023;22:973-975.
    PubMed    


  71. ADAMS D, Sekijima Y, Conceicao I, Waddington-Cruz M, et al
    Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment.
    Lancet Neurol. 2023;22:1061-1074.
    PubMed     Abstract available


    October 2023
  72. MIRELMAN A, Rochester L, Simuni T, Hausdoff JM, et al
    Digital mobility measures to predict Parkinson's disease.
    Lancet Neurol. 2023 Oct 18:S1474-4422(23)00376.
    PubMed    


  73. SPOSATO LA, Field TS, Schnabel RB, Wachter R, et al
    Towards a new classification of atrial fibrillation detected after a stroke or a transient ischaemic attack.
    Lancet Neurol. 2023 Oct 11:S1474-4422(23)00326.
    PubMed     Abstract available


  74. AL-SHAHI SALMAN R, Stephen J, Tierney JF, Lewis SC, et al
    Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials.
    Lancet Neurol. 2023 Oct 11:S1474-4422(23)00315.
    PubMed     Abstract available


  75. KAMEL H
    Reassessing the implications of atrial fibrillation detected after stroke.
    Lancet Neurol. 2023 Oct 11:S1474-4422(23)00406.
    PubMed    


  76. BRUSCA SB, Albert MA
    Balancing the scales of adversity: a socioecological approach to reducing the global burden of stroke and cardiovascular disease.
    Lancet Neurol. 2023 Oct 9:S1474-4422(23)00386.
    PubMed    


  77. WATKINS DA
    Policy priorities for preventing stroke-related mortality and disability worldwide.
    Lancet Neurol. 2023 Oct 9:S1474-4422(23)00387.
    PubMed    


  78. FEIGIN VL, Owolabi MO
    Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization-Lancet Neurology Commission.
    Lancet Neurol. 2023 Oct 6:S1474-4422(23)00277.
    PubMed    


  79. MARCUCCI M, Chan MTV, Smith EE, Absalom AR, et al
    Prevention of perioperative stroke in patients undergoing non-cardiac surgery.
    Lancet Neurol. 2023;22:946-958.
    PubMed     Abstract available


  80. IZZY S, Grashow R, Radmanesh F, Chen P, et al
    Long-term risk of cardiovascular disease after traumatic brain injury: screening and prevention.
    Lancet Neurol. 2023;22:959-970.
    PubMed     Abstract available


    September 2023
  81. HUGGER SS, Do TP, Ashina H, Goicochea MT, et al
    Migraine in older adults.
    Lancet Neurol. 2023 Sep 13:S1474-4422(23)00206.
    PubMed     Abstract available


  82. LABEIT B, Michou E, Hamdy S, Trapl-Grundschober M, et al
    The assessment of dysphagia after stroke: state of the art and future directions.
    Lancet Neurol. 2023;22:858-870.
    PubMed     Abstract available


  83. FENG W
    Diagnosis of post-stroke dysphagia: towards better treatment.
    Lancet Neurol. 2023;22:778-779.
    PubMed    


  84. OSPEL JM, Goyal M
    Prehospital triage in acute stroke: which questions to ask?
    Lancet Neurol. 2023;22:771-772.
    PubMed    


  85. D'GAMA AM, Mulhern S, Sheidley BR, Boodhoo F, et al
    Evaluation of the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in infantile epilepsy (Gene-STEPS): an international, multicentre, pilot cohort study.
    Lancet Neurol. 2023;22:812-825.
    PubMed     Abstract available


  86. GUTERUD M, Fagerheim Bugge H, Roislien J, Kramer-Johansen J, et al
    Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial.
    Lancet Neurol. 2023;22:800-811.
    PubMed     Abstract available


    August 2023
  87. ODDO M, Taccone FS, Petrosino M, Badenes R, et al
    The Neurological Pupil index for outcome prognostication in people with acute brain injury (ORANGE): a prospective, observational, multicentre cohort study.
    Lancet Neurol. 2023 Aug 28:S1474-4422(23)00271.
    PubMed     Abstract available


  88. RIZIG M, Bandres-Ciga S, Makarious MB, Ojo OO, et al
    Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study.
    Lancet Neurol. 2023 Aug 23:S1474-4422(23)00283.
    PubMed     Abstract available


  89. SOLOMON AJ, Arrambide G, Brownlee WJ, Flanagan EP, et al
    Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.
    Lancet Neurol. 2023;22:750-768.
    PubMed     Abstract available


  90. MEADOR KJ, Cohen MJ, Loring DW, Matthews AG, et al
    Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort study.
    Lancet Neurol. 2023;22:712-722.
    PubMed     Abstract available


  91. MAYNARD G, Kannan R, Liu J, Wang W, et al
    Soluble Nogo-Receptor-Fc decoy (AXER-204) in patients with chronic cervical spinal cord injury in the USA: a first-in-human and randomised clinical trial.
    Lancet Neurol. 2023;22:672-684.
    PubMed     Abstract available


  92. GILADI N, Alcalay RN, Cutter G, Gasser T, et al
    Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet Neurol. 2023;22:661-671.
    PubMed     Abstract available


    July 2023
  93. ENGLISH C, Ramage E
    Secondary stroke prevention: more questions than answers.
    Lancet Neurol. 2023 Jul 25:S1474-4422(23)00278.
    PubMed    


  94. SCHWARZBACH CJ, Eichner FA, Rucker V, Hofmann AL, et al
    The structured ambulatory post-stroke care program for outpatient aftercare in patients with ischaemic stroke in Germany (SANO): an open-label, cluster-randomised controlled trial.
    Lancet Neurol. 2023 Jul 14:S1474-4422(23)00216.
    PubMed     Abstract available


  95. DESBOROUGH MJR, Al-Shahi Salman R, Stanworth SJ, Havard D, et al
    Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial.
    Lancet Neurol. 2023;22:557-567.
    PubMed     Abstract available


  96. FRISONI GB, van der Flier W
    STRIVEing to describe small vessel disease.
    Lancet Neurol. 2023;22:548-549.
    PubMed    


  97. GRANIT V, Benatar M, Kurtoglu M, Miljkovic MD, et al
    Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
    Lancet Neurol. 2023;22:578-590.
    PubMed     Abstract available


  98. CORBOY JR, Fox RJ, Kister I, Cutter GR, et al
    Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.
    Lancet Neurol. 2023;22:568-577.
    PubMed     Abstract available


  99. MEISEL A
    Are CAR T cells the answer to myasthenia gravis therapy?
    Lancet Neurol. 2023;22:545-546.
    PubMed    


    June 2023
  100. VAN DER MERWE J
    Stroke care quality-why recognition matters.
    Lancet Neurol. 2023;22:471.
    PubMed    


  101. HAYWARD KS, Bernhardt J
    Aspiring to restore arm and hand function after stroke.
    Lancet Neurol. 2023;22:464-465.
    PubMed    


    May 2023
  102. DUERING M, Biessels GJ, Brodtmann A, Chen C, et al
    Neuroimaging standards for research into small vessel disease-advances since 2013.
    Lancet Neurol. 2023 May 23:S1474-4422(23)00131.
    PubMed     Abstract available


  103. KOEMANS EA, Chhatwal JP, van Veluw SJ, van Etten ES, et al
    Progression of cerebral amyloid angiopathy: a pathophysiological framework.
    Lancet Neurol. 2023 May 23:S1474-4422(23)00114.
    PubMed     Abstract available


  104. HOWARD JF JR, Bresch S, Genge A, Hewamadduma C, et al
    Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet Neurol. 2023;22:395-406.
    PubMed     Abstract available


  105. BRIL V, Druzdz A, Grosskreutz J, Habib AA, et al
    Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
    Lancet Neurol. 2023;22:383-394.
    PubMed     Abstract available


  106. KASKI D, Koohi N, Haider S, Chandratheva A, et al
    The hyperacute vestibular syndrome: ear or brain?
    Lancet Neurol. 2023;22:377-378.
    PubMed    


    April 2023
  107. WU S, Anderson CS
    Antiplatelets for secondary stroke prevention in China.
    Lancet Neurol. 2023 Apr 27:S1474-4422(23)00130.
    PubMed    


  108. PAN Y, Meng X, Yuan B, Johnston SC, et al
    Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial.
    Lancet Neurol. 2023 Apr 27:S1474-4422(23)00113.
    PubMed     Abstract available


  109. LAVALLEE PC, Charles H, Albers GW, Caplan LR, et al
    Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study.
    Lancet Neurol. 2023;22:320-329.
    PubMed     Abstract available


  110. SAMUELS N, van de Graaf RA, Mulder MJHL, Brown S, et al
    Admission systolic blood pressure and effect of endovascular treatment in patients with ischaemic stroke: an individual patient data meta-analysis.
    Lancet Neurol. 2023;22:312-319.
    PubMed     Abstract available


  111. BERNHARDT J, Corbett D, Dukelow S, Savitz S, et al
    The International Stroke Recovery and Rehabilitation Alliance.
    Lancet Neurol. 2023;22:295-296.
    PubMed    


  112. MAZIGHI M
    The quest for optimal blood pressure management after stroke.
    Lancet Neurol. 2023;22:285-286.
    PubMed    


  113. FEIGIN VL, Brainin M, Martins SCO
    The polypill from a public-health perspective.
    Lancet Neurol. 2023;22:294-295.
    PubMed    


    March 2023
  114. TSIVGOULIS G, Katsanos AH, Sandset EC, Turc G, et al
    Thrombolysis for acute ischaemic stroke: current status and future perspectives.
    Lancet Neurol. 2023 Mar 9:S1474-4422(22)00519.
    PubMed     Abstract available


  115. REIFF T, Eckstein HH, Mansmann U, Hacke W, et al
    Treatment of asymptomatic carotid stenosis in SPACE-2 - Authors' reply.
    Lancet Neurol. 2023;22:198-199.
    PubMed    


  116. SPENCE JD
    Treatment of asymptomatic carotid stenosis in SPACE-2.
    Lancet Neurol. 2023;22:197-198.
    PubMed    


  117. GOEL A, Soteriou I, Normando E
    Treatment of asymptomatic carotid stenosis in SPACE-2.
    Lancet Neurol. 2023;22:197.
    PubMed    


  118. THORNTON CA, Moxley RT 3rd, Eichinger K, Heatwole C, et al
    Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial.
    Lancet Neurol. 2023;22:218-228.
    PubMed     Abstract available


  119. LIPTON RB, Croop R, Stock DA, Madonia J, et al
    Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.
    Lancet Neurol. 2023;22:209-217.
    PubMed     Abstract available


    February 2023
  120. ALEMSEGED F, Nguyen TN, Coutts SB, Cordonnier C, et al
    Endovascular thrombectomy for basilar artery occlusion: translating research findings into clinical practice.
    Lancet Neurol. 2023 Feb 10:S1474-4422(22)00483.
    PubMed     Abstract available


  121. MONICHE F, Cabezas-Rodriguez JA, Valverde R, Escudero-Martinez I, et al
    Safety and efficacy of intra-arterial bone marrow mononuclear cell transplantation in patients with acute ischaemic stroke in Spain (IBIS trial): a phase 2, randomised, open-label, standard-of-care controlled, multicentre trial.
    Lancet Neurol. 2023;22:137-146.
    PubMed     Abstract available


  122. SAVITZ SI
    Intra-arterial bone marrow mononuclear cells for stroke.
    Lancet Neurol. 2023;22:105-106.
    PubMed    


    January 2023
  123. GOYAL M, Singh N, Ospel J
    Clinical trials in stroke in 2022: new answers and questions.
    Lancet Neurol. 2023;22:9-10.
    PubMed    


  124. JENSEN M, Suling A, Metzner A, Schnabel RB, et al
    Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial.
    Lancet Neurol. 2023;22:45-54.
    PubMed     Abstract available


  125. DROUIN E, Pasquini M, Hautecoeur P
    The advent of stroke units.
    Lancet Neurol. 2023;22:31.
    PubMed    


  126. CALVERT P, Gupta D, Lip GYH
    Early atrial fibrillation rhythm control after stroke.
    Lancet Neurol. 2023;22:3-4.
    PubMed    


  127. PENSATO U, Romoli M, Lazzarin SM, Marcheselli S, et al
    The shortage of thrombolytics for stroke: a call for action.
    Lancet Neurol. 2023;22:28.
    PubMed    


    December 2022
  128. ROALDSEN MB, Eltoft A, Wilsgaard T, Christensen H, et al
    Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial.
    Lancet Neurol. 2022 Dec 19:S1474-4422(22)00484.
    PubMed     Abstract available


  129. MUIR KW
    Treatment of wake-up stroke: stick or TWIST?
    Lancet Neurol. 2022 Dec 19:S1474-4422(22)00515.
    PubMed    


  130. THE LANCET NEUROLOGY
    Tackling the burden of stroke with primordial prevention.
    Lancet Neurol. 2022;21:1061.
    PubMed    


  131. SOILEAU MJ, Aldred J, Budur K, Fisseha N, et al
    Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
    Lancet Neurol. 2022;21:1099-1109.
    PubMed     Abstract available


    November 2022
  132. KUHLMANN T, Moccia M, Coetzee T, Cohen JA, et al
    Multiple sclerosis progression: time for a new mechanism-driven framework.
    Lancet Neurol. 2022 Nov 18:S1474-4422(22)00289.
    PubMed     Abstract available


  133. CHURILOV L, Bivard A, Parsons MW
    Tenecteplase versus alteplase for early treatment of ischaemic stroke - Authors' reply.
    Lancet Neurol. 2022;21:959.
    PubMed    


  134. HUDAIB AR
    Tenecteplase versus alteplase for early treatment of ischaemic stroke.
    Lancet Neurol. 2022;21:959.
    PubMed    


    October 2022
  135. HOU C, Lan J, Lin Y, Song H, et al
    Chronic remote ischaemic conditioning in patients with symptomatic intracranial atherosclerotic stenosis (the RICA trial): a multicentre, randomised, double-blind sham-controlled trial in China.
    Lancet Neurol. 2022 Oct 27. pii: S1474-4422(22)00335.
    PubMed     Abstract available


  136. GANESH A, Smith EE, Hill MD
    Remote ischaemic conditioning for stroke prevention.
    Lancet Neurol. 2022 Oct 27. pii: S1474-4422(22)00438.
    PubMed    


  137. HOBEANU C, Lavallee PC, Charles H, Labreuche J, et al
    Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke: an international, prospective cohort study.
    Lancet Neurol. 2022;21:889-898.
    PubMed     Abstract available


  138. REIFF T, Eckstein HH, Mansmann U, Jansen O, et al
    Carotid endarterectomy or stenting or best medical treatment alone for moderate-to-severe asymptomatic carotid artery stenosis: 5-year results of a multicentre, randomised controlled trial.
    Lancet Neurol. 2022;21:877-888.
    PubMed     Abstract available


  139. BURTON A
    Valeria Caso: because women have strokes too.
    Lancet Neurol. 2022;21:873.
    PubMed    


  140. CHRISTENSEN H
    Long-term disability after transient ischaemic attack or minor stroke.
    Lancet Neurol. 2022;21:859-860.
    PubMed    


    September 2022
  141. PETER-DEREX L, Philippeau F, Garnier P, Andre-Obadia N, et al
    Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Neurol. 2022;21:781-791.
    PubMed     Abstract available


  142. SYKES L, Akpalu A, Gordon C, Cullen L, et al
    Developing stroke care services in west Africa.
    Lancet Neurol. 2022;21:778-779.
    PubMed    


  143. VAN DEN BERG SA, Uniken Venema SM, Reinink H, Hofmeijer J, et al
    Prehospital transdermal glyceryl trinitrate in patients with presumed acute stroke (MR ASAP): an ambulance-based, multicentre, randomised, open-label, blinded endpoint, phase 3 trial.
    Lancet Neurol. 2022 Sep 1. pii: S1474-4422(22)00333.
    PubMed     Abstract available


  144. SANDSET EC, Walter S, Song L
    The challenges of large-scale prehospital stroke trials.
    Lancet Neurol. 2022 Sep 1. pii: S1474-4422(22)00356.
    PubMed    


    August 2022
  145. BRAININ M, Grisold W, Hankey GJ, Norrving B, et al
    Time to revise primary prevention guidelines for stroke and cardiovascular disease.
    Lancet Neurol. 2022;21:686-687.
    PubMed    


    June 2022
  146. BAAK LM, Wagenaar N, van der Aa NE, Groenendaal F, et al
    Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study.
    Lancet Neurol. 2022;21:528-536.
    PubMed     Abstract available


  147. GONZALEZ F, Ferriero DM
    Stem cells for perinatal stroke.
    Lancet Neurol. 2022;21:497-499.
    PubMed    


  148. THE LANCET NEUROLOGY
    No area of stroke research should be left behind.
    Lancet Neurol. 2022;21:495.
    PubMed    


    May 2022
  149. ROTHWELL PM
    20 years of improvement in stroke care: the rewards from finally funding more research.
    Lancet Neurol. 2022;21:402-404.
    PubMed    


    April 2022
  150. BIVARD A, Zhao H, Churilov L, Campbell BCV, et al
    Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial.
    Lancet Neurol. 2022 Apr 29. pii: S1474-4422(22)00171.
    PubMed     Abstract available


  151. KVISTAD CE, Naess H, Helleberg BH, Idicula T, et al
    Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.
    Lancet Neurol. 2022 Apr 29. pii: S1474-4422(22)00124.
    PubMed     Abstract available


  152. COUTTS SB, Yu AYX
    Tenecteplase for acute stroke: the thrombolysis puzzle.
    Lancet Neurol. 2022 Apr 29. pii: S1474-4422(22)00172.
    PubMed    


  153. HILL G, Regan S, Francis R
    Research priorities to improve stroke outcomes.
    Lancet Neurol. 2022;21:312-313.
    PubMed    


    March 2022
  154. BONATI LH, Jansen O, de Borst GJ, Brown MM, et al
    Management of atherosclerotic extracranial carotid artery stenosis.
    Lancet Neurol. 2022;21:273-283.
    PubMed     Abstract available


    February 2022
  155. ZHAO J, Yuan F, Song C, Yin R, et al
    Safety and efficacy of three enteral feeding strategies in patients with severe stroke in China (OPENS): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.
    Lancet Neurol. 2022 Feb 24. pii: S1474-4422(22)00010.
    PubMed     Abstract available


  156. DZIEWAS R
    Nutrition in acute stroke management: food for thought.
    Lancet Neurol. 2022 Feb 24. pii: S1474-4422(22)00078.
    PubMed    


  157. GUTIERREZ J, Turan TN, Hoh BL, Chimowitz MI, et al
    Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment.
    Lancet Neurol. 2022 Feb 7. pii: S1474-4422(21)00376.
    PubMed     Abstract available


  158. SAMARASEKERA U
    Jeyaraj Pandian: passionate about improving stroke care in India.
    Lancet Neurol. 2022;21:120.
    PubMed    


    January 2022
  159. BAILLIEUL S, Dekkers M, Brill AK, Schmidt MH, et al
    Sleep apnoea and ischaemic stroke: current knowledge and future directions.
    Lancet Neurol. 2022;21:78-88.
    PubMed     Abstract available


  160. PUY L, Cordonnier C
    Stroke research in 2021: insights into the reorganisation of stroke care.
    Lancet Neurol. 2022;21:2-3.
    PubMed    


    December 2021
  161. FEIGIN VL
    Primary stroke prevention: useful thresholds?
    Lancet Neurol. 2021 Dec 16. pii: S1474-4422(21)00458.
    PubMed    


    November 2021
  162. SCHREUDER FHBM, van Nieuwenhuizen KM, Hofmeijer J, Vermeer SE, et al
    Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial.
    Lancet Neurol. 2021;20:907-916.
    PubMed     Abstract available


    September 2021
  163. PANDIAN JD, Sebastian IA
    Integrated approach to stroke burden: are we doing enough?
    Lancet Neurol. 2021 Sep 3. pii: S1474-4422(21)00287.
    PubMed    



  164. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet Neurol. 2021 Sep 3. pii: S1474-4422(21)00252.
    PubMed     Abstract available


  165. CASO V, Mosconi MG
    Lessons to be learned in intracerebral haemorrhage research.
    Lancet Neurol. 2021 Sep 2. pii: S1474-4422(21)00296.
    PubMed    


  166. HOWARD DPJ, Rothwell PM
    Asymptomatic carotid stenosis and stroke risk - Authors' reply.
    Lancet Neurol. 2021;20:699.
    PubMed    


  167. ABBOTT A
    Asymptomatic carotid stenosis and stroke risk.
    Lancet Neurol. 2021;20:698-699.
    PubMed    


  168. ROTHWELL PM, Buchan AM
    A new thrombolytic drug for acute ischaemic stroke.
    Lancet Neurol. 2021;20:687-689.
    PubMed    


  169. GUSEV EI, Martynov MY, Nikonov AA, Shamalov NA, et al
    Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4.5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.
    Lancet Neurol. 2021;20:721-728.
    PubMed     Abstract available


    July 2021
  170. BANDINI F, Vestito L, Filippi L
    Prehospital scales in acute ischaemic stroke management.
    Lancet Neurol. 2021;20:504.
    PubMed    


  171. DUVEKOT MHC, Venema E, Kerkhoff H, Dippel DWJ, et al
    Prehospital scales in acute ischaemic stroke management - Authors' reply.
    Lancet Neurol. 2021;20:504-505.
    PubMed    


    June 2021
  172. LI L, Poon MTC, Samarasekera NE, Perry LA, et al
    Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies.
    Lancet Neurol. 2021;20:437-447.
    PubMed     Abstract available


  173. HAEUSLER KG, Kirchhof P, Kunze C, Tutuncu S, et al
    Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study.
    Lancet Neurol. 2021;20:426-436.
    PubMed     Abstract available


  174. CHENG X, Dong Q
    Towards individualised secondary prevention after intracerebral haemorrhage.
    Lancet Neurol. 2021;20:411-413.
    PubMed    


  175. WASSERLAUF J, Volgman AS
    Monitoring for atrial fibrillation after stroke.
    Lancet Neurol. 2021;20:410-411.
    PubMed    


    May 2021
  176. SAMARASEKERA U
    Michael Moskowitz: solving the puzzle of migraine.
    Lancet Neurol. 2021 May 17. pii: S1474-4422(21)00141.
    PubMed    


  177. JORDAN LC, DeBaun MR, Donahue MJ
    Advances in neuroimaging to improve care in sickle cell disease.
    Lancet Neurol. 2021;20:398-408.
    PubMed     Abstract available


  178. HACHINSKI V, Avan A, Gilliland J, Oveisgharan S, et al
    A new definition of brain health.
    Lancet Neurol. 2021;20:335-336.
    PubMed    


    April 2021
  179. WEAVER NA, Kuijf HJ, Aben HP, Abrigo J, et al
    Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts.
    Lancet Neurol. 2021 Apr 23. pii: S1474-4422(21)00060.
    PubMed     Abstract available


  180. PANTONI L, Salvadori E
    Location of infarcts and post-stroke cognitive impairment.
    Lancet Neurol. 2021 Apr 23. pii: S1474-4422(21)00107.
    PubMed    


  181. BEST JG, Ambler G, Wilson D, Lee KJ, et al
    Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from
    Lancet Neurol. 2021;20:294-303.
    PubMed     Abstract available


  182. GREENBERG SM
    Cerebral microbleeds and prediction of intracranial haemorrhage.
    Lancet Neurol. 2021;20:252-254.
    PubMed    


  183. ZIAI WC, Al-Kawaz M
    Blood pressure management after endovascular therapy.
    Lancet Neurol. 2021;20:248-249.
    PubMed    


  184. LAUMANN TO, Ortega M, Hoyt CR, Seider NA, et al
    Brain network reorganisation in an adolescent after bilateral perinatal strokes.
    Lancet Neurol. 2021;20:255-256.
    PubMed    


    March 2021
  185. SCHMIDT R, Hofer E
    Identifying novel genetic risk loci for lacunar stroke.
    Lancet Neurol. 2021 Mar 25. pii: S1474-4422(21)00099.
    PubMed    


  186. TRAYLOR M, Persyn E, Tomppo L, Klasson S, et al
    Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies.
    Lancet Neurol. 2021 Mar 25. pii: S1474-4422(21)00031.
    PubMed     Abstract available


  187. ENGELTER ST, Traenka C, Gensicke H, Schaedelin SA, et al
    Aspirin versus anticoagulation in cervical artery dissection (TREAT-CAD): an open-label, randomised, non-inferiority trial.
    Lancet Neurol. 2021 Mar 22. pii: S1474-4422(21)00044.
    PubMed     Abstract available


  188. HOWARD DPJ, Gaziano L, Rothwell PM
    Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis.
    Lancet Neurol. 2021;20:193-202.
    PubMed     Abstract available


  189. VAN DIJCK JTJM, Kompanje EJO, Nederkoorn PJ, Peul WC, et al
    Advanced consent for acute stroke trials - Authors' reply.
    Lancet Neurol. 2021;20:170-171.
    PubMed    


  190. SHAMY M, Dewar B, Niznick N, Nicholls S, et al
    Advanced consent for acute stroke trials.
    Lancet Neurol. 2021;20:170.
    PubMed    


  191. SPENCE JD
    Treatment of asymptomatic carotid stenosis.
    Lancet Neurol. 2021;20:163-165.
    PubMed    


    February 2021
  192. MAZIGHI M, Richard S, Lapergue B, Sibon I, et al
    Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial.
    Lancet Neurol. 2021 Feb 26. pii: S1474-4422(20)30483.
    PubMed     Abstract available


    January 2021
  193. DUVEKOT MHC, Venema E, Rozeman AD, Moudrous W, et al
    Comparison of eight prehospital stroke scales to detect intracranial large-vessel occlusion in suspected stroke (PRESTO): a prospective observational study.
    Lancet Neurol. 2021 Jan 7. pii: S1474-4422(20)30439.
    PubMed     Abstract available


  194. GOYAL M, Marko M
    Optimising prehospital stroke triage in a changing landscape.
    Lancet Neurol. 2021 Jan 7. pii: S1474-4422(20)30488.
    PubMed    


  195. TSIVGOULIS G, Katsanos AH
    Important advances in stroke research in 2020.
    Lancet Neurol. 2021;20:2-3.
    PubMed    


    December 2020
  196. WU S, Anderson CS
    Healthy eating for secondary stroke prevention.
    Lancet Neurol. 2020 Dec 18. pii: S1474-4422(20)30450.
    PubMed    


  197. ENGLISH C, MacDonald-Wicks L, Patterson A, Attia J, et al
    The role of diet in secondary stroke prevention.
    Lancet Neurol. 2020 Dec 18. pii: S1474-4422(20)30433.
    PubMed     Abstract available


  198. SILBERGLEIT R, Dickert NW
    Context and principles must drive alternatives to consent in emergency research.
    Lancet Neurol. 2020;19:968-969.
    PubMed    


    November 2020
  199. THE LANCET NEUROLOGY
    A unified European action plan on stroke.
    Lancet Neurol. 2020 Nov 6. pii: S1474-4422(20)30409.
    PubMed    


    October 2020
  200. MERETOJA A, Yassi N, Wu TY, Churilov L, et al
    Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial.
    Lancet Neurol. 2020 Oct 28. pii: S1474-4422(20)30369.
    PubMed     Abstract available


  201. KOMPANJE EJO, van Dijck JTJM, Chalos V, van den Berg SA, et al
    Informed consent procedures for emergency interventional research in patients with traumatic brain injury and ischaemic stroke.
    Lancet Neurol. 2020 Oct 21. pii: S1474-4422(20)30276.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Stroke is free of charge.